Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: Efficacy and safety data according to liver function

Clinical and Translational Oncology

Volumn 15, Issue 2, 2013, Pages 146-153

  Zugazagoitia, Jon ^a   Manzano, Aránzazu ^a   Sastre, Javier ^a,b   Ladero, Jose María ^a,b   Puente, Javier ^a,b   Díaz Rubio, Eduardo ^a,b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Child Pugh score; Compensated cirrhosis; Decompensated cirrhosis; Hepatocellular carcinoma; Liver related events; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84878541724     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0902-3     Document Type: Article

References (19)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576
2. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine-kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
4. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55-76
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncology 10:25-34
7. Zhang T, Ding X, Wei D, Cheng P, SU X, Liu H et al (2010) Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 21:326-332
8. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A et al (2010) Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 22:391-398
9. D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217-231
10. Letón E, Zuluaga P (2005) Relationships among tests for censored data. Biom J 47:377-387
11. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H et al (2009) Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43:489-495
12. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Finger A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300
13. Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A et al (2011) Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 34:1193-1201
14. Pinter M, Sieghart W, Graziadel I, Vogel W, Maieron A, Königsberg R et al (2009) Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14:70-76
15. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST et al (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115:428-436
16. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M et al (2010) Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 22:1106-1110
17. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC et al (2011) Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 68:1285-1290
18. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C et al (2011) Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 4:40-44
19. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A et al (2011) Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 34:949-959